UCB Defeats Cipla Bid to Nix Patents for Nayzilam Seizure Spray

Cipla Ltd. failed to convince a federal judge in Delaware to invalidate two patents covering UCB Inc.'s Nayzilam that it conceded its proposed copy of the seizure-treatment nasal spray infringes.

Cipla didn’t prove US Patent Nos. 8,217,033 and 8,809,322 invalid as anticipated or obvious, Judge Jennifer L. Hall said in an opinion unsealed Thursday. The May 15 ruling, which blocks Cipla from launching its generic version until the patents expire in January 2028, stems from a four-day bench trial held in the US District Court for the District of Delaware in October 2023.

The patents cover nasal-spray formulations for midazolam, ...